First-in-class iberdomide has been given accelerated approval under the Zenbexus brand name, alongside Johnson & Johnson and ...

AstraZeneca is leaving no stone unturned in its effort to make baxdrostat the first aldosterone synthase inhibitor (ASI) to get approval for hard-to-treat hypertension. The FDA has now started a ...

After reporting mixed clinical results in a phase 3 trial, Pfizer and Valneva have filed their Lyme disease vaccine candidate PF-07307405 in the EU, and the EMA has started its review. The six-valent ...

The FDA has published its long-awaited update to guidance to make sure clinical trials more closely reflect the range of patients that might be treated with a new therapy in the real world. The draft ...

Shares in ADC Therapeutics were trading down more than 50% today after a non-Hodgkin lymphoma (NHL) trial showed more deaths with its Zynlonta drug compared to standard therapy. The LOTIS-5 trial is ...

A year ago, Astellas was celebrating the first-in-class approval of its claudin 18.2-targeting cancer drug Vyloy for gastric cancers. Now, a bid to expand its label into pancreatic cancer has hit the ...

Indeed, GLP-1 therapies currently bring with them the inconvenience of subcutaneous injections, the difficulty of titration, ...

AbbVie, Bristol Myers Squibb, and Novartis have filed separate lawsuits in Illinois, each seeking to overturn a recently ...

There’s a personalisation crisis in today’s marketing. Nearly 99% of marketers believe personalisation helps strengthen ...

Actio is the third acquisition for Jazz in the last few years, coming after it bought Chimerix for $935 million last year and ...

Under the terms of the deal, ‌Lantheus' shareholders will get $102.50 per share in cash when the deal closes, along with the ...

ADC Therapeutics' chances of upgrading its accelerated approval for diffuse large B-cell lymphoma therapy Zynlonta to a full approval have taken a knock. In its second-quarter res ...